Xiaoning (Lizzy) Zhang

Associate

    Xiaoning (Lizzy) Zhang

    Associate

    lizzy.zhang@lw.com

    Profile

    Lizzy Zhang is an associate in the Hong Kong office of Latham & Watkins and a member of the Corporate Department.

    Lizzy’s practices span an array of areas including securities offerings, cross-border mergers and acquisitions, and other general corporate matters.

    Prior to joining Latham, Lizzy spent five years at the Chinese Ministry of Foreign Affairs. She successively served in the Department of Treaties and Law as well as in several Chinese embassies in East Africa in political and press affairs such as China’s Africa aid and Belt & Road Initiative.

    Lizzy has also worked as a trainee attorney in a Chinese law firm’s head office in Beijing, where she drafted, reviewed, and negotiated documents on domestic IPOs and cross-border acquisitions, including due diligence reports, share purchase agreements, and legal opinions.

    Experience

    Lizzy’s recent experience includes advising:

    • The underwriters on the HK$1.4 billion Ch.18C initial public offering of CiDi, a provider of intelligent driving products for commercial vehicles in China, on The Stock Exchange of Hong Kong
    • The joint sponsors and underwriters on the HK$1.85 billion initial public offering of Caocao, a leading ride-hailing platform in China, on The Stock Exchange of Hong Kong
    • The joint sponsors and underwriters on the HK$1.4 billion initial public offering of Drinda, a leading specialized manufacturer of photovoltaic cells, on The Stock Exchange of Hong Kong
    • The underwriters on the initial public offering of Yuanbao, a leader in the insurtech industry, on the NASDAQ
    • The initial purchasers on the offering of US$960 million in aggregate principal amount of 0.50% convertible senior notes due 2030 by Qifu Technology
    • The underwriters on the US$97.5 million initial public offering on Nasdaq Global Market for Adlai Nortye, a clinical-stage biotechnology company focused on the development of innovative cancer therapies
    • The underwriters on the US$140 million initial public offering of American depositary shares on the NASDAQ for Adagene Inc., a clinical-stage biopharmaceutical company in China
    • Kuaishou Technology, a leading content community and social platform globally, on its US$5.4 billion initial public offering and listing on the Main Board of the Hong Kong Stock Exchange
    • The underwriters on the US$620 million initial public offering of American Depositary Shares on the New York Stock Exchange for Yatsen Holding Limited, the parent company of Chinese cosmetics brand Perfect Diary
    • The underwriters on the US$33 million initial public offering of American depository shares on the NASDAQ of Quhuo Limited, the largest workforce operational solution platform in China
    • The underwriters on the US$40 million initial public offering of American depositary shares on the NASDAQ of EHang Holdings Limited, a world’s leading autonomous aerial vehicle technology platform company

    Qualifications

    Bar Qualification

    • Hong Kong (Registered Foreign Lawyer)
    • New York

    Education

    • LLM, Harvard Law School, 2018
    • LLB, China Foreign Affairs University, 2009

    Languages Spoken

    • Chinese (Mandarin)
    • English
    • French

    Practices

    News & Insights

    Read More